Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

ABBOTT LABORATORIES

ClinicalTrials.gov lists ABBOTT LABORATORIES as lead sponsor of 601 trials, counting the companies grouped under it.

US Industry Manufacturer CIK 0000001800
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Companies grouped under this page Companies grouped under this page 32 Disease areas Disease areas 338 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 1 Journals published in Journals published in 504 US granted patents US granted patents 1 SEC-reported annual financials SEC-reported annual financials 11 Financing and grant events Financing and grant events 16 FDA inspection record FDA inspection record 1 Companies grouped under this page Companies grouped under this page 32 Disease areas Disease areas 338 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 1 Journals published in Journals published in 504 US granted patents US granted patents 1 SEC-reported annual financials SEC-reported annual financials 11 Financing and grant events Financing and grant events 16 FDA inspection record FDA inspection record 1

Rows recorded per section (log scale)

9 more sections with rows · 7 sections measured, none recorded

Logo Abbott Laboratories, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers ABBOTT LABORATORIES and 32 companies grouped under it: 601 lead-sponsored trials (0 its own, 601 in the grouped companies) and 77 legal-entity registrations (10 its own, 67 in the grouped companies).

Get the ABBOTT LABORATORIES report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Companies grouped under this page (32)

Shown in this order: most lead trials first.

Companies grouped under this page
Company Lead trials Legal entities
ABBOTT 362 26
ABBOTT (JIAXING) NUTRITION CO. LTD. 156 2
ABBOTT DIABETES CARE LIMITED 43 2
ABBOTT PRODUCTS (PHILIPPINES), INC. 11 1
Abbott Point of Care 8 0

Showing 5 of 32 member companies.

Start your 14-day trial Email me all 32 member companies as a PDF

Disease areas (338)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Diabetes Mellitus 124
HIV Infections 83
Diabetes Mellitus, Type 2 57
Arthritis, Rheumatoid 48
Coronary Disease 45

Showing 5 of 338 disease areas.

Start your 14-day trial Email me the first 50 disease areas as a PDF

Trials by start year as sponsor or collaborator (1)

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1

No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Journals published in (504)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of the American College of Cardiology 70
The New England journal of medicine 67
Circulation 59
European heart journal 34
JACC. Cardiovascular interventions 29

Showing 5 of 504 journals.

Start your 14-day trial Email me the first 50 journals as a PDF

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
6,363 462 2025-12-30

SEC-reported annual financials (11)

Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.

SEC-reported annual financials
Fiscal year Revenue (USD) Net income (USD) R&D (USD)
2025 44,328,000,000 6,524,000,000 2,942,000,000
2024 41,950,000,000 13,402,000,000 2,844,000,000
2023 40,109,000,000 5,723,000,000 2,741,000,000
2022 43,653,000,000 6,933,000,000 2,888,000,000
2021 43,075,000,000 7,071,000,000 2,742,000,000
2020 34,608,000,000 4,495,000,000 2,420,000,000
2019 31,904,000,000 3,687,000,000 2,440,000,000
2018 30,578,000,000 2,368,000,000 2,300,000,000
2017 27,390,000,000 477,000,000 2,260,000,000
2016 20,853,000,000 1,400,000,000 1,447,000,000

Showing 10 of 11 fiscal years.

Start your 14-day trial Email me all 11 fiscal years as a PDF

Financing and grant events (16)

Shown in this order: most recent first.

Financing and grant events
Date Round type Amount (USD) Source
2026-03-23 Other financing not disclosed Sec extracted
2026-03-09 Debt financing not disclosed Sec extracted
2026-02-25 Debt financing 19,966,487,500 Edgar offerings
2026-02-23 Follow-on offering not disclosed Edgar offerings
2026-02-23 Other financing not disclosed Edgar offerings

Showing 5 of 16 events.

Start your 14-day trial Email me all 16 events as a PDF

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 149

FDA recalls (100)

Shown in this order: most recent first.

FDA recalls
Product Classification Initiated
Alinity ci-series System Control Module (SCM), REF: 03R70-01, 03R70-20 Class II 2025-11-13
Brand Name: Alinity hq Analyzer Product Name: Alinity hq Analyzer Model/Catalog Number: 09P68-01 Software Version: 5.0 to 5.10.1 for OUS, 5.7 and 5.10.1 in the US Product Description: Alinity hq Analyzer Component: No Class II 2025-09-18
Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-01 Software Version: All software versions Product Description: CELL-DYN Ruby Component: No Class II 2025-03-18
Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-03 Software Version: All software versions Product Description: CELL-DYN Ruby Component: No Class II 2025-03-18
Brand Name: CELL-DYN Ruby Product Name: CELL-DYN Ruby Model/Catalog Number: 08H67-10 Software Version: All software versions Product Description: CELL-DYN Ruby Component: No Class II 2025-03-18

Showing 5 of 100 recalls.

Start your 14-day trial Email me the first 50 recalls as a PDF

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
48 2025-12-19

Manufacturing and distribution sites (5)

Shown in this order: severity rank then name.

Manufacturing and distribution sites
Facility Location Regulators Member organization
ABBOTT LABORATORIES Abbott Park, US FDA
ABBOTT LABORATORIES Irving, US FDA
ABBOTT LABORATORIES IRVING, US FDA
ABBOTT LABORATORIES Sunnyvale, US FDA
ABBOTT LABORATORIES Lake Forest, US FDA

Climate targets, as filed (1)

Climate targets, as filed
Reporting year Net-zero target
2025 not disclosed

Workforce and board diversity, as filed (1)

Workforce and board diversity, as filed
Reporting year Workforce % women Board % women
2025 46.0% not disclosed

Organization relationships (239)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Government of the United States of America Co sponsors trial with 23
Merck & Co., Inc., Rahway, NJ, USA (United States) Co sponsors trial with 15
Eisai (Japan) Co sponsors trial with 10
Iqvia Holdings Inc. Uses vendor 7
Roche (Switzerland) Co sponsors trial with 7

Showing 5 of 239 relationships.

Start your 14-day trial Email me the first 50 relationships as a PDF

Latest dated events (8,256)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-11 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 8,256 events.

Start your 14-day trial Email me the first 50 events as a PDF

CLIA clinical laboratory certificates (3)

Shown in this order: active first, then certificate type.

CLIA clinical laboratory certificates
Lab Certificate Status
ABBOTT LABORATORIES Certificate of waiver Active
ABBOTT LABORATORIES Certificate of waiver Active
ABBOTT LABORATORIES Certificate of waiver Active

Biomarkers this organization publishes on (53)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
INS 4
ALB 3
CRP 3
GPT 3
ERBB2 2

Showing 5 of 53 biomarkers.

Start your 14-day trial Email me the first 50 biomarkers as a PDF

Not on this page

Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, fda warning letters, fda untitled letters, and biomarker capability evidence.